These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 36622756

  • 21. In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.
    Santerre Henriksen A, Jeannot K, Oliver A, Perry JD, Pletz MW, Stefani S, Morrissey I, Longshaw C, ARTEMIS Study Investigators.
    Microbiol Spectr; 2024 Apr 02; 12(4):e0383623. PubMed ID: 38483164
    [Abstract] [Full Text] [Related]

  • 22. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
    Ortiz de la Rosa JM, Nordmann P, Poirel L.
    J Antimicrob Chemother; 2019 Jul 01; 74(7):1934-1939. PubMed ID: 31225611
    [Abstract] [Full Text] [Related]

  • 23. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
    O'Neall D, Juhász E, Tóth Á, Urbán E, Szabó J, Melegh S, Katona K, Kristóf K.
    Acta Microbiol Immunol Hung; 2020 Mar 26; 67(1):61-65. PubMed ID: 32208923
    [Abstract] [Full Text] [Related]

  • 24. Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.
    Buyukyanbolu E, Genc L, Cyr EA, Karakus M, Comert F, Otlu B, Aktas E, Nicolau DP.
    Eur J Clin Microbiol Infect Dis; 2024 Sep 26; 43(9):1787-1794. PubMed ID: 38995343
    [Abstract] [Full Text] [Related]

  • 25. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
    Weber C, Schultze T, Göttig S, Kessel J, Schröder A, Tietgen M, Besier S, Burbach T, Häussler S, Wichelhaus TA, Hack D, Kempf VAJ, Hogardt M.
    Microbiol Spectr; 2022 Oct 26; 10(5):e0169722. PubMed ID: 36190424
    [Abstract] [Full Text] [Related]

  • 26. In Vitro Activity of New β-Lactam-β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019.
    Guo Y, Han R, Jiang B, Ding L, Yang F, Zheng B, Yang Y, Wu S, Yin D, Zhu D, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group.
    Microbiol Spectr; 2022 Aug 31; 10(4):e0185422. PubMed ID: 35862963
    [Abstract] [Full Text] [Related]

  • 27. In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
    Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF.
    Int J Antimicrob Agents; 2023 May 31; 61(5):106772. PubMed ID: 36878411
    [Abstract] [Full Text] [Related]

  • 28. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS.
    Int J Antimicrob Agents; 2021 Nov 31; 58(5):106439. PubMed ID: 34547421
    [Abstract] [Full Text] [Related]

  • 29. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
    Barnes MD, Taracila MA, Rutter JD, Bethel CR, Galdadas I, Hujer AM, Caselli E, Prati F, Dekker JP, Papp-Wallace KM, Haider S, Bonomo RA.
    mBio; 2018 Dec 11; 9(6):. PubMed ID: 30538183
    [Abstract] [Full Text] [Related]

  • 30. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
    Kresken M, Körber-Irrgang B, Korte-Berwanger M, Pfennigwerth N, Gatermann SG, Seifert H, German Carbapenem Resistance Study Group.
    Int J Antimicrob Agents; 2020 Jun 11; 55(6):105959. PubMed ID: 32325200
    [Abstract] [Full Text] [Related]

  • 31. Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy.
    Bassetti M, Monti G, Henriksen AS, Longshaw C.
    Antimicrob Resist Infect Control; 2024 Aug 26; 13(1):91. PubMed ID: 39183351
    [Abstract] [Full Text] [Related]

  • 32. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.
    Bonnin RA, Bernabeu S, Emeraud C, Creton E, Vanparis O, Naas T, Jousset AB, Dortet L.
    Int J Antimicrob Agents; 2022 Oct 26; 60(4):106660. PubMed ID: 35988666
    [Abstract] [Full Text] [Related]

  • 33. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A, Tan E, McCarthy KL, Paterson DL.
    Pathology; 2018 Dec 26; 50(7):748-752. PubMed ID: 30392710
    [Abstract] [Full Text] [Related]

  • 34. Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies).
    Hernández-García M, García-Castillo M, Bou G, Cercenado E, Delgado-Valverde M, Oliver A, Pitart C, Rodríguez-Lozano J, Tormo N, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V, Vieira AR, Ramalheira E, Sancho L, Diogo J, Ferreira R, Cruz H, Chaves C, Duarte J, Pássaro L, Díaz-Regañón J, Cantón R.
    Microbiol Spectr; 2022 Oct 26; 10(5):e0292722. PubMed ID: 36043877
    [Abstract] [Full Text] [Related]

  • 35. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M, Sutherland C, Nicolau DP.
    Antimicrob Agents Chemother; 2017 Oct 26; 61(10):. PubMed ID: 28739780
    [Abstract] [Full Text] [Related]

  • 36. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
    Lee SY, Gill CM, Nicolau DP, ERACE-PA Global Study Group.
    J Antimicrob Chemother; 2023 Dec 01; 78(12):2795-2800. PubMed ID: 37840005
    [Abstract] [Full Text] [Related]

  • 37. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb 01; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 38. Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil.
    Carvalho TN, Kobs VC, Hille D, Deglmann RC, Melo LH, França PHC.
    Rev Soc Bras Med Trop; 2023 Feb 01; 56():. PubMed ID: 36700602
    [Abstract] [Full Text] [Related]

  • 39. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK.
    Int J Antimicrob Agents; 2018 Feb 01; 51(2):181-189. PubMed ID: 28993143
    [Abstract] [Full Text] [Related]

  • 40. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
    Mirza HC, Hortaç E, Koçak AA, Demirkaya MH, Yayla B, Güçlü AÜ, Başustaoğlu A.
    J Glob Antimicrob Resist; 2020 Mar 01; 20():334-338. PubMed ID: 31568882
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.